A Phase 3 interventional study of ALD403 (Eptinezumab) in Migraine Disorder, sponsored by Alder Biopharmaceuticals, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-04-21.
Sponsored by Alder Biopharmaceuticals, Inc. (part of H. Lundbeck A/S) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.
Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 15th largest by enrollment, is one of 2 that started in 2016, is one of 13 in phase 3, and was the 6th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 12–17
Dr George Medvedev · Sites in Canada
Ages 19–75
By country, each count listing its studies:
eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 128 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 193 across the 21 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 21 have an industry lead sponsor. The 5 most frequent:
This study is registered under Alder Biopharmaceuticals, Inc., one of the names counted as H. Lundbeck A/S. Under that name alone:
Alder Biopharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
23 studies in Migraine Disorders by H. Lundbeck A/S: 3 open now, 3 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, this one is the 17th largest by enrollment, is one of 2 that started in 2016, is one of 11 in phase 3, and was the 6th registered.
H. Lundbeck A/S’s Migraine Disorders studies by the year they started, since 2012.
3 of the studies testing eptinezumab in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT07191145Phase 3Sunnybrook Health Sciences CentreEary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | 2027-06-30 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing eptinezumab in Migraine Disorders, from their registry updates:
Among H. Lundbeck A/S’s 23 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALD403 (Eptinezumab) Dose Level 1 (IV)
Biological: ALD403 (Eptinezumab)
Also known as: Eptinezumab-jjmr, Vyepti
Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)
Treatment emergent adverse events were defined as adverse events with start date and time on or after the date and time of the initial study drug infusion.
Time frame: 104 Weeks
Number of Participants With a Clinically Significant Electrocardiogram
Overall investigator interpretation of participant electrocardiogram
Time frame: Baseline, Day 0 Postdose, Week 12, 24, 36, 48 60, 72 and 84 (Predose and Postdose), and Week 104
Number of Participants With Any Clinically Significant Laboratory Values
Each of the laboratory values that were reported as abnormal and clinically significant and entered as adverse events in the database.
Time frame: 104 Weeks
Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior on Columbia-Suicide Severity Rating Scale (C-SSRS)
Baseline responses are collected at screening and assess suicidal ideation in the past 6 months. Post baseline reports the worst assessment of suicidal ideation since the last visit for all post baseline visits.
Time frame: 104 Weeks
Number of Participants With Any Clinically Significant (CS) Changes in Vital Signs
Changes in vital signs that were considered clinically meaningful or clinically significant (CS) by the Investigator
Time frame: 104 Weeks
Patient Global Impression of Change (PGIC) at Week 104
The PGIC includes a single question concerning the participant's impression of the change in their disease status since the start of the study. Seven responses are possible: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.
Time frame: Week 104
Change in Baseline of Short Form Health Survey (SF-36 v 2.0) Scale Scores
The SF-36 is a health survey consisting of 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks (scale range: 0=worst to 100=best). Increases from baseline indicate improvement.
Time frame: Baseline to Week 12
Health Related Quality of Life (EQ-5D-5L) at Week 12
The EQ-5D-5L is a descriptive health-related quality of life states consisting of 5 dimensions/questions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.
Time frame: Week 12
Change in Baseline of Headache Impact Test (HIT-6) Score
The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assess over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact). The change in baseline will be calculated from the average scores.
Time frame: Baseline, Week 1-4, Week 9-12
Change in Most Bothersome Symptom at Week 48
The Investigator verbally obtained the most bothersome symptom associated with the participant's migraine during the screening visit. The most bothersome symptom may include nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, or other migraine related symptoms. Participants were asked to rate the improvement in this symptom from screening on a seven-point scale.
Time frame: Baseline to Week 48
Change From Baseline of Migraine Disability Assessment (MIDAS) Total Score
The MIDAS questionnaire measures the effect headaches have on the participant's daily functioning. MIDAS is composed of five questions that ask about the participant's performance over the past 3 months. The response to each question is provided in number of days which are summed to determine the MIDAS total score and level of disability: 0-5, MIDAS Grade I, little or no disability; 6-10, MIDAS Grade II, mild disability; 11-20, MIDAS Grade III, moderate disability; 21+, MIDAS Grade IV, severe disability; A higher value represents a worse outcome.
Time frame: Baseline to Week 12
Development of Anti-ALD403 Antibody by Visit
Serum blood samples were taken at visits to test for the development of antibodies to ALD403, or anti-drug antibodies (ADA). Participants who tested positive for anti-ALD403 antibodies at the time of the last study visit were asked to provide up to 2 additional blood samples for immunogenicity testing at approximately 3 month intervals for up to 6 months.
Time frame: Baseline, Week 2, 4, 8, 12, 24, 36, 48, 72 and 104
Summary of Neutralizing Properties of Anti-ALD403 Antibodies by Visit
Any samples that were positive for anti-ALD403 antibody, there was additional testing to characterize the anti-ALD403 antibody for the potential to neutralize (NAb) ALD403 activity.
Time frame: Baseline, Week 2, 4, 8, 12, 24, 36, 48, 72 and 104
| Milestone | 300 mg ALD403 |
|---|---|
| Started | 128 |
| Participants treated | 128 |
| Completed | 106 |
| Not completed | 22 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Study burden | 9 |
Treatment emergent adverse events were defined as adverse events with start date and time on or after the date and time of the initial study drug infusion.
| Participants | 300 mg ALD403 |
|---|---|
| Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) | 91 |
Overall investigator interpretation of participant electrocardiogram
| Participants | 300 mg ALD403 |
|---|---|
| Baseline | 0 |
| Day 0 Postdose | 1 |
| Week 12 Predose | 0 |
| Week 12 Postdose | 0 |
| Week 24 Predose | 0 |
| Week 24 Postdose | 0 |
| Week 36 Predose | 0 |
| Week 36 Postdose | 0 |
| Week 48 Predose | 0 |
| Week 48 Postdose | 0 |
| Week 60 Predose | 1 |
| Week 60 Postdose | 1 |
| Week 72 Predose | 1 |
| Week 72 Postdose | 1 |
| Week 84 Predose | 1 |
| Week 84 Postdose | 0 |
| Week 104 | 1 |
Each of the laboratory values that were reported as abnormal and clinically significant and entered as adverse events in the database.
| Participants | 300 mg ALD403 |
|---|---|
| Hematocrit Decreased | 1 |
| Hemoglobin Decreased | 1 |
| Blood Glucose Increased | 1 |
| Hypertriglyceridemia | 1 |
| Blood Potassium Decreased | 1 |
| Hypokalemia | 1 |
| Blood Mercury Abnormal | 1 |
| Hypercholesterolemia | 1 |
| Hyperlipidemia | 1 |
Baseline responses are collected at screening and assess suicidal ideation in the past 6 months. Post baseline reports the worst assessment of suicidal ideation since the last visit for all post baseline visits.
| Participants | 300 mg ALD403 |
|---|---|
| Participants Experiencing Suicidal Ideation | 0 |
| Participants Experiencing Suicidal Behavior | 0 |
Changes in vital signs that were considered clinically meaningful or clinically significant (CS) by the Investigator
| Participants | 300 mg ALD403 |
|---|---|
| Number of CS changes in diastolic blood pressure | 0 |
| Number of CS changes in systolic blood pressure | 0 |
| Number of CS changes in heart rate value | 0 |
The PGIC includes a single question concerning the participant's impression of the change in their disease status since the start of the study. Seven responses are possible: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.
| Participants | 300 mg ALD403 |
|---|---|
| Very Much Improved | 47 |
| Much Improved | 33 |
| Minimally Improved | 11 |
| No Change | 5 |
| Minimally Worse | 0 |
| Much Worse | 0 |
| Very Much Worse | 0 |
The SF-36 is a health survey consisting of 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks (scale range: 0=worst to 100=best). Increases from baseline indicate improvement.
| score on a scale | 300 mg ALD403 |
|---|---|
| Bodily Pain | 5.8 ± 10.06 |
| General Health | 1.6 ± 6.46 |
| Mental Component | 1.9 ± 7.89 |
| Mental Health | 1.4 ± 7.86 |
| Physical Component | 4.5 ± 7.08 |
| Physical Functioning | 2.9 ± 6.15 |
| Role Emotional | 2.3 ± 9.09 |
| Role Physical | 4.8 ± 8.34 |
| Social Functioning | 4.9 ± 9.13 |
| Vitality | 3.0 ± 7.90 |
The EQ-5D-5L is a descriptive health-related quality of life states consisting of 5 dimensions/questions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.
| Participants | 300 mg ALD403 |
|---|---|
| Mobility — No problems | 110 |
| Mobility — Slight problems | 11 |
| Mobility — Moderate problems | 3 |
| Mobility — Severe problems | 0 |
| Mobility — Extreme problems | 0 |
| Self-care — No problems | 121 |
| Self-care — Slight problems | 3 |
| Self-care — Moderate problems | 0 |
| Self-care — Severe problems | 0 |
| Self-care — Extreme problems | 0 |
| Usual Activities — No problems | 95 |
| Usual Activities — Slight problems | 18 |
| Usual Activities — Moderate problems | 11 |
| Usual Activities — Severe problems | 0 |
| Usual Activities — Extreme problems | 0 |
| Pain/Discomfort — No problems | 55 |
| Pain/Discomfort — Slight problems | 42 |
| Pain/Discomfort — Moderate problems | 22 |
| Pain/Discomfort — Severe problems | 5 |
| Pain/Discomfort — Extreme problems | 0 |
| Anxiety/Depression — No problems | 96 |
| Anxiety/Depression — Slight problems | 22 |
| Anxiety/Depression — Moderate problems | 6 |
| Anxiety/Depression — Severe problems | 0 |
| Anxiety/Depression — Extreme problems | 0 |
The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assess over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact). The change in baseline will be calculated from the average scores.
| score on a scale | 300 mg ALD403 |
|---|---|
| Week 1-4 | -8.0 ± 8.06 |
| Week 9-12 | -7.9 ± 7.96 |
The Investigator verbally obtained the most bothersome symptom associated with the participant's migraine during the screening visit. The most bothersome symptom may include nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, or other migraine related symptoms. Participants were asked to rate the improvement in this symptom from screening on a seven-point scale.
| Participants | 300 mg ALD403 |
|---|---|
| Very Much Improved | 40 |
| Much Improved | 44 |
| Minimally Improved | 17 |
| No Change | 11 |
| Minimally Worse | 0 |
| Much Worse | 0 |
| Very Much Worse | 0 |
The MIDAS questionnaire measures the effect headaches have on the participant's daily functioning. MIDAS is composed of five questions that ask about the participant's performance over the past 3 months. The response to each question is provided in number of days which are summed to determine the MIDAS total score and level of disability: 0-5, MIDAS Grade I, little or no disability; 6-10, MIDAS Grade II, mild disability; 11-20, MIDAS Grade III, moderate disability; 21+, MIDAS Grade IV, severe disability; A higher value represents a worse outcome.
| score on a scale | 300 mg ALD403 |
|---|---|
| Change From Baseline of Migraine Disability Assessment (MIDAS) Total Score | -36.3 ± 51.85 |
Serum blood samples were taken at visits to test for the development of antibodies to ALD403, or anti-drug antibodies (ADA). Participants who tested positive for anti-ALD403 antibodies at the time of the last study visit were asked to provide up to 2 additional blood samples for immunogenicity testing at approximately 3 month intervals for up to 6 months.
| Participants | 300 mg ALD403 |
|---|---|
| Day 0: ADA Results — ADA Positive | 0 |
| Day 0: ADA Results — ADA Negative | 128 |
| Week 2 : ADA Results — ADA Positive | 1 |
| Week 2 : ADA Results — ADA Negative | 126 |
| Week 4 : ADA Results — ADA Positive | 0 |
| Week 4 : ADA Results — ADA Negative | 126 |
| Week 8 : ADA Results — ADA Positive | 7 |
| Week 8 : ADA Results — ADA Negative | 118 |
| Week 12 : ADA Results — ADA Positive | 11 |
| Week 12 : ADA Results — ADA Negative | 112 |
| Week 24 : ADA Results — ADA Positive | 21 |
| Week 24 : ADA Results — ADA Negative | 99 |
| Week 36 : ADA Results — ADA Positive | 9 |
| Week 36 : ADA Results — ADA Negative | 109 |
| Week 48 : ADA Results — ADA Positive | 6 |
| Week 48 : ADA Results — ADA Negative | 107 |
| Week 72 : ADA Results — ADA Positive | 4 |
| Week 72 : ADA Results — ADA Negative | 97 |
| Week 104 : ADA Results — ADA Positive | 0 |
| Week 104 : ADA Results — ADA Negative | 96 |
Any samples that were positive for anti-ALD403 antibody, there was additional testing to characterize the anti-ALD403 antibody for the potential to neutralize (NAb) ALD403 activity.
| Participants | 300 mg ALD403 |
|---|---|
| Day 0: NAb Results — NAb Positive | 0 |
| Day 0: NAb Results — NAb Negative | 0 |
| Week 2 : NAb Results — NAb Positive | 0 |
| Week 2 : NAb Results — NAb Negative | 1 |
| Week 4 : NAb Results — NAb Positive | 0 |
| Week 4 : NAb Results — NAb Negative | 0 |
| Week 8 : NAb Results — NAb Positive | 3 |
| Week 8 : NAb Results — NAb Negative | 4 |
| Week 12 : NAb Results — NAb Positive | 8 |
| Week 12 : NAb Results — NAb Negative | 3 |
| Week 24 : NAb Results — NAb Positive | 5 |
| Week 24 : NAb Results — NAb Negative | 16 |
| Week 36 : NAb Results — NAb Positive | 1 |
| Week 36 : NAb Results — NAb Negative | 8 |
| Week 48 : NAb Results — NAb Positive | 1 |
| Week 48 : NAb Results — NAb Negative | 5 |
| Week 72 : NAb Results — NAb Positive | 0 |
| Week 72 : NAb Results — NAb Negative | 4 |
| Week 104 : NAb Results — NAb Positive | 0 |
| Week 104 : NAb Results — NAb Negative | 0 |
Collected over Baseline to Week 104 (end of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 300 mg ALD403 | 0/128 (0%) | 5/128 (3.9%) | 49/128 (38.3%) |
| Event | 300 mg ALD403 |
|---|---|
| Anaphylactic ReactionImmune system disorders | 1/128 |
| PneumoniaInfections and infestations | 1/128 |
| Diabetes Mellitus Inadequate ControlMetabolism and nutrition disorders | 1/128 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/128 |
| Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/128 |
| Conversion DisorderPsychiatric disorders | 1/128 |
| Event | 300 mg ALD403 |
|---|---|
| NasopharyngitisInfections and infestations | 18/128 |
| SinusitisInfections and infestations | 10/128 |
| Upper respiratory tract infectionInfections and infestations | 10/128 |
| InfluenzaInfections and infestations | 8/128 |
| BronchitisInfections and infestations | 7/128 |
| MigraineNervous system disorders | 7/128 |
Safety Population includes all participants who received study drug.
| Age, Continuous(years) | 300 mg ALD403 |
|---|---|
| Mean | 41.5 ± 11.33 |
| Sex: Female, Male(Participants) | 300 mg ALD403 |
|---|---|
| Female | 109 |
| Male | 19 |
| Ethnicity (NIH/OMB)(Participants) | 300 mg ALD403 |
|---|---|
| Hispanic or Latino | 26 |
| Not Hispanic or Latino | 102 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | 300 mg ALD403 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 122 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | 300 mg ALD403 |
|---|---|
| United States | 128 |
| Duration of migraine diagnosis at baseline(years) | 300 mg ALD403 |
|---|---|
| Mean | 21.2 ± 11.65 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Apr 2018, 16 months.
Results were first posted in Apr 2020, 2 years after primary completion. A results delay was requested in May 2019.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 16 months is below that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eptinezumab
Alder Biopharmaceuticals, Inc. →